Ustekinumab biosimilar - Formycon
Alternative Names: FYB 202; Otulfi; Ustekinumab-aauzLatest Information Update: 06 Jun 2025
At a glance
- Originator Formycon
- Developer Formycon; Fresenius Kabi
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Antiulcers; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Interleukin 12 inhibitors; Interleukin 23 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Crohn's disease; Plaque psoriasis; Psoriatic arthritis; Ulcerative colitis
- Registered Immunological disorders